Youssef S - Search Results

1

The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.

Stüve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, Hirschberg DL, Brickey WJ, Soos JM, Piskurich JF, Chapman HA, Zamvil SS. Stüve O, et al. Among authors: youssef s. J Immunol. 2002 Dec 15;169(12):6720-32. doi: 10.4049/jimmunol.169.12.6720. J Immunol. 2002. PMID: 12471103

2

The potential therapeutic role of statins in central nervous system autoimmune disorders.

Stüve O, Youssef S, Dunn S, Slavin AJ, Steinman L, Zamvil SS. Stüve O, et al. Among authors: youssef s. Cell Mol Life Sci. 2003 Nov;60(11):2483-91. doi: 10.1007/s00018-003-3146-0. Cell Mol Life Sci. 2003. PMID: 14625690 Review.

3

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. Youssef S, et al. Nature. 2002 Nov 7;420(6911):78-84. doi: 10.1038/nature01158. Nature. 2002. PMID: 12422218

4

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, Patarroyo JC, Stüve O, Sobel RA, Steinman L, Zamvil SS. Weber MS, et al. Among authors: youssef s. Nat Med. 2007 Aug;13(8):935-43. doi: 10.1038/nm1620. Epub 2007 Aug 5. Nat Med. 2007. PMID: 17676050

5

Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate.

Soos JM, Stüve O, Youssef S, Bravo M, Johnson HM, Weiner HL, Zamvil SS. Soos JM, et al. Among authors: youssef s. J Immunol. 2002 Sep 1;169(5):2231-5. doi: 10.4049/jimmunol.169.5.2231. J Immunol. 2002. PMID: 12193686

6

Statins as potential therapeutic agents in neuroinflammatory disorders.

Stüve O, Youssef S, Steinman L, Zamvil SS. Stüve O, et al. Among authors: youssef s. Curr Opin Neurol. 2003 Jun;16(3):393-401. doi: 10.1097/01.wco.0000073942.19076.d1. Curr Opin Neurol. 2003. PMID: 12858078 Review.

7

Statins and their potential targets in multiple sclerosis therapy.

Stüve O, Prod'homme T, Slavin A, Youssef S, Dunn S, Steinman L, Zamvil SS. Stüve O, et al. Among authors: youssef s. Expert Opin Ther Targets. 2003 Oct;7(5):613-22. doi: 10.1517/14728222.7.5.613. Expert Opin Ther Targets. 2003. PMID: 14498824 Review.

8

Statins in the treatment of central nervous system autoimmune disease.

Weber MS, Youssef S, Dunn SE, Prod'homme T, Neuhaus O, Stuve O, Greenwood J, Steinman L, Zamvil SS. Weber MS, et al. Among authors: youssef s. J Neuroimmunol. 2006 Sep;178(1-2):140-8. doi: 10.1016/j.jneuroim.2006.06.006. Epub 2006 Jul 24. J Neuroimmunol. 2006. PMID: 16860400 Review.

9

Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.

Weber MS, Prod'homme T, Youssef S, Dunn SE, Steinman L, Zamvil SS. Weber MS, et al. Among authors: youssef s. J Neuroinflammation. 2014 Feb 6;11:29. doi: 10.1186/1742-2094-11-29. J Neuroinflammation. 2014. PMID: 24498870 Free PMC article.

10

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin.

Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L. Dunn SE, et al. Among authors: youssef s. J Exp Med. 2006 Feb 20;203(2):401-12. doi: 10.1084/jem.20051129. Epub 2006 Feb 13. J Exp Med. 2006. PMID: 16476765 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

767 results

Search Page